Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H2 2018
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2018'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).
The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2018' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 2 respectively.
Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Central Nervous System, Infectious Disease, Ophthalmology and Respiratory which include indications Atopic Dermatitis, Non-Alcoholic Steatohepatitis (NASH), Actinic (Solar) Keratosis, Acute Lung Injury, Genital Warts (Condylomata Acuminata), Inflammation, Intermediate Uveitis, Multiple Sclerosis, Posterior Uveitis, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2018'; Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Tumor necrosis factor receptor 1 (TNFR1) is a ubiquitous membrane receptor that binds tumor necrosis factor-alpha (TNFalpha). This receptor activates NF-kappaB, mediate apoptosis and function as a regulator of inflammation. Mutations in this receptor were found to be associated with tumor necrosis factor associated periodic syndrome (TRAPS).
The report 'Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2018' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 1, 1 and 2 respectively.
Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Central Nervous System, Infectious Disease, Ophthalmology and Respiratory which include indications Atopic Dermatitis, Non-Alcoholic Steatohepatitis (NASH), Actinic (Solar) Keratosis, Acute Lung Injury, Genital Warts (Condylomata Acuminata), Inflammation, Intermediate Uveitis, Multiple Sclerosis, Posterior Uveitis, Psoriasis, Retinitis Pigmentosa (Retinitis), Rheumatoid Arthritis and Warts.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
Baliopharm AG
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
May 09, 2017: Eyevensys Announces the First-in-Human Treatment with its Groundbreaking EyeCET ElectroTransfection Technology for Eye Diseases
Apr 20, 2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
Apr 11, 2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
May 31, 2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Feb 18, 2016: Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Companies Involved in Therapeutics Development
Baliopharm AG
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Promethera Biosciences SA
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Drug Profiles
Atrosab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Atrosimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize TNFRSF1A for Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EYS-606 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2862277 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize TNFR-1 for Atopic Dermatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Discontinued Products
Tumor Necrosis Factor Receptor Superfamily Member 1A (Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A) - Product Development Milestones
Featured News & Press Releases
May 09, 2017: Eyevensys Announces the First-in-Human Treatment with its Groundbreaking EyeCET ElectroTransfection Technology for Eye Diseases
Apr 20, 2017: Eyevensys Receives Approval from the UK Medicines and Healthcare products Regulatory Agency to advance its EyeCET platform into clinical development
Apr 11, 2017: Eyevensys Receives Approval from the French Product Security Regulatory Agency ANSM to advance its EyeCET platform into clinical development
May 31, 2016: Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Feb 18, 2016: Eyevensys Receives Orphan Drug Designation in the European Union for EYS606 for the Non-Infectious Uveitis
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Baliopharm AG, H2 2018
Pipeline by Eyevensys SAS, H2 2018
Pipeline by G&E Corp, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Inflamalps SA, H2 2018
Pipeline by Promethera Biosciences SA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Baliopharm AG, H2 2018
Pipeline by Eyevensys SAS, H2 2018
Pipeline by G&E Corp, H2 2018
Pipeline by GlaxoSmithKline Plc, H2 2018
Pipeline by Inflamalps SA, H2 2018
Pipeline by Promethera Biosciences SA, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Baliopharm AG
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Promethera Biosciences SA
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Baliopharm AG
Eyevensys SAS
G&E Corp
GlaxoSmithKline Plc
Inflamalps SA
Promethera Biosciences SA
